---
search:
  boost: 2 
---

# Antifungals

This is a subcategory of Infectious Disease Agents.

## Formulary

### Preferred

| Preferred    | Generic Name | Quantity | Time (Days) |
| :----------- | :----------- | :------: | :---------: |
| Fluconazole  |              |          |             |
| Flucytosine  |              |          |             |
| Griseofulvin |              |          |             |
| Ketoconazole |              |          |             |
| Terbinafine  |              |          |             |

### Non-Preferred

| Non-Preferred        | Generic Name | Quantity | Time (Days) |
| :------------------- | :----------- | :------: | :---------: |
| Brexafemme           |              |          |             |
| Cresemba             |              |          |             |
| Itraconazole         |              |          |             |
| Noxafil Susp         |              |          |             |
| Oravig               |              |          |             |
| Posaconazole         |              |          |             |
| Tolsura              |              |          |             |
| Vivjoa <sup>PA</sup> |
| Voriconazole         |              |          |             |

## Authorizations

**Length of Authorizations**: Based on indication

**All Authorizations**: Must be prescribed in accordance with FDA approved labeling

## Criteria

### Non-Preferred

Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **7 days** with at least **one preferred** drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Oteseconazole (Vivjoa)

Additional Oteseconazole (Vivjoa) Criteria

- Must provide documentation of at least three symptomatic episodes of vulvovaginal candidiasis in the past 12 months
- Must provide documentation of non-reproductive potential (i.e, post-menopausal)
- Must have had an inadequate clinical response of at least **180 day** maintenance course with oral fluconazole shown by documentation of more than **one** breakthrough infection 

### Additional Information

- Requests may be authorized if:
    - The infection is caused by an organism resistant to **ALL** preferred antifungals (must provide diagnosis and any culture/sensitivity results)
    - The patient is completing a course of therapy that was started in the hospital or other similar location or was started before Medicaid eligibility, only the remaining course will be authorized


### Subsequent Authorization

Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring, **AND** medical necessity for continued use

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=80)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=26)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
